Insider Selling: CRISPR Therapeutics AG (NASDAQ:CRSP) CEO Sells 30,000 Shares of Stock

CRISPR Therapeutics AG (NASDAQ:CRSP) CEO Samarth Kulkarni sold 30,000 shares of the firm’s stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $55.62, for a total value of $1,668,600.00. Following the completion of the transaction, the chief executive officer now directly owns 196,540 shares in the company, valued at $10,931,554.80. The trade was a 13.24 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Samarth Kulkarni also recently made the following trade(s):

• On Monday, October 14th, Samarth Kulkarni sold 4,293 shares of CRISPR Therapeutics stock. The stock was sold at an average price of $46.28, for a total value of $198,680.04.

CRISPR Therapeutics Stock Performance

Shares of CRISPR Therapeutics stock opened at $47.25 on Friday. The business’s 50 day moving average price is $47.88 and its 200 day moving average price is $52.04. The company has a market cap of $4.03 billion, a price-to-earnings ratio of -16.70 and a beta of 1.67. CRISPR Therapeutics AG has a one year low of $43.42 and a one year high of $91.10.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($1.01) earnings per share for the quarter, beating the consensus estimate of ($1.42) by $0.41. CRISPR Therapeutics had a negative net margin of 118.13% and a negative return on equity of 12.15%. The business had revenue of $0.60 million during the quarter, compared to analysts’ expectations of $6.65 million. During the same quarter in the prior year, the company posted ($1.41) EPS. On average, analysts predict that CRISPR Therapeutics AG will post -5.2 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on CRSP. Truist Financial dropped their price target on shares of CRISPR Therapeutics from $120.00 to $100.00 and set a “buy” rating for the company in a research report on Monday, August 12th. Stifel Nicolaus decreased their price target on CRISPR Therapeutics from $60.00 to $59.00 and set a “hold” rating on the stock in a report on Tuesday, August 6th. Needham & Company LLC reiterated a “buy” rating and set a $84.00 target price on shares of CRISPR Therapeutics in a research report on Wednesday, November 6th. Rodman & Renshaw began coverage on CRISPR Therapeutics in a report on Friday, August 2nd. They issued a “buy” rating and a $90.00 price target on the stock. Finally, StockNews.com raised shares of CRISPR Therapeutics to a “sell” rating in a report on Thursday, November 7th. Three equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $74.94.

Hedge Funds Weigh In On CRISPR Therapeutics

Large investors have recently made changes to their positions in the stock. Global Trust Asset Management LLC lifted its stake in CRISPR Therapeutics by 150.0% during the second quarter. Global Trust Asset Management LLC now owns 500 shares of the company’s stock worth $27,000 after purchasing an additional 300 shares in the last quarter. Larson Financial Group LLC lifted its stake in CRISPR Therapeutics by 95.5% during the 2nd quarter. Larson Financial Group LLC now owns 565 shares of the company’s stock worth $31,000 after acquiring an additional 276 shares in the last quarter. GPS Wealth Strategies Group LLC grew its position in CRISPR Therapeutics by 99.7% in the 2nd quarter. GPS Wealth Strategies Group LLC now owns 615 shares of the company’s stock valued at $33,000 after acquiring an additional 307 shares in the last quarter. Itau Unibanco Holding S.A. purchased a new stake in CRISPR Therapeutics during the second quarter worth about $35,000. Finally, Darwin Wealth Management LLC purchased a new position in shares of CRISPR Therapeutics in the third quarter valued at approximately $43,000. 69.20% of the stock is currently owned by institutional investors and hedge funds.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.